Estate Planners Group’s 10x Genomics TXG Stock Holding History

Estate Planners Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40	Closed	-$652	–	380
2025 Q4	$652	Buy	+40	New	+$604	﹤0.01%	431

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Estate Planners Group's TXG Position: Q1 2026 in Review

Estate Planners Group sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 40 shares — an estimated $652 sold.

Estate Planners Group first reported a position in TXG in Q4 2025 and held it in 1 quarter. The position peaked at $652 in Q4 2025. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Estate Planners Group reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
Estate Planners Group sold 40 10x Genomics shares in Q1 2026, an estimated $652.
Estate Planners Group first reported a position in 10x Genomics in Q4 2025 and held it in 1 quarter.
Estate Planners Group's 10x Genomics position peaked at $652 in Q4 2025.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Estate Planners Group's 13F filing for Q1 2026, filed 11 May 2026.